Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries

none14siIntroduction: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant delivers a continuous intravitreal corticosteroid dose for the treatment of refractory diabetic macular oedema (DMO). The aim of this study was to assess the impact of an FAc intravitreal implant on intraocular pressure (IOP). Methods: We retrospectively collected anonymised data on the patients’ characteristics, DMO treatment, and IOP and IOP-lowering treatments before and after the FAc intravitreal implant between September 2013 and March 2020 in several European centres. Results: A total of 221 eyes from 179 patients were included. The mean follow-up duration was 13.4 (± 12.5, range 2.4–33.5) months. Overall, 194 eyes (88.2%) had received an intravitreal dexamethasone injection before the FAc intravitreal implant. For 25 eyes (11.3%) there was a history of glaucoma, and 52 eyes (23.5%) had previous IOP-lowering treatment. Mean IOP before injection was 14.7 (3.4) mmHg and increased to 16.9 (3.7) mmHg 12 months after injection (P < 0.0001). During follow-up, 55 eyes (24.9%) required the addition or initiation of topical IOP-lowering medication, only one patient (0.5%) had laser trabeculoplasty and one patient (0.5%) a minimally invasive glaucoma surgery, and no patient required incisional IOP-lowering surgery. Conclusion: The FAc intravitreal implant led to substantial IOP elevation. This elevation was monitored most of the time with addition or initiation of topical IOP-lowering medication.openLebrize S.; Arnould L.; Bourredjem A.; Busch C.; Rehak M.; Massin P.; Barbosa-Breda J.; Lupidi M.; Mariotti C.; Hamza M.; Grise-Dulac A.; Gabrielle P.-H.; Baillif S.; Creuzot-Garcher C.Lebrize, S.; Arnould, L.; Bourredjem, A.; Busch, C.; Rehak, M.; Massin, P.; Barbosa-Breda, J.; Lupidi, M.; Mariotti, C.; Hamza, M.; Grise-Dulac, A.; Gabrielle, P. -H.; Baillif, S.; Creuzot-Garcher, C

Fractalkine et son récepteur dans le glaucome chronique à angle ouvert

PARIS7-Xavier Bichat (751182101) / SudocSudocFranceF

Objective Assessment of Crystalline Lens Opacity Level by Measuring Ocular Light Scattering With a Double-Pass System

PURPOSE: To assess the crystalline lens opacity level by measuring ocular light scattering with a double-pass system. DESIGN: Prospective, single-center, cross-sectional study. METHODS: Two hundred fifty-three eyes of 135 patients referred for cataract evaluation were enrolled. Patients with corneal or retinal anomalies potentially impairing ocular transparency were excluded. Lens opacification was assessed by the Lens opacities classification system III. Optical Quality Analysis System (Visiometrics SL) measurements provided ocular Modulation Transfer Function cutoff frequency and Objective Scatter Index. Best-corrected visual acuity and Quality of Vision questionnaire scores (Rasch-scaled) were recorded. We analyzed correlations between visual acuity, type and severity of cataract, Optical Quality Analysis System measurements, and discomfort level in each group. RESULTS: In patients with best-corrected visual acuity better than 20/32, we found correlations between Objective Scatter Index, Modulation Transfer Function, and visual acuity (r = 0.4, P < .0001). The Objective Scatter Index, Modulation Transfer Function, and visual acuity were correlated with each type of cataract. In patients with good visual acuity and moderate functional symptoms, the Objective Scatter Index values also were correlated to the severity of posterior subcapsular cataract (r = 0.4, P = .0006). CONCLUSIONS: Patients with incipient cataract may report visual discomfort, despite minor lens opacity on slit-lamp examination, minor loss of best-corrected visual acuity, or both. The measurement of ocular scattering with the Optical Quality Analysis System device may be a useful tool in the preoperative evaluation of patients with early cataract. (Am J Ophthalmol 2013;155:629-635. (C) 2013 by Elsevier Inc. All rights reserved.

Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries

International audienceINTRODUCTION: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant delivers a continuous intravitreal corticosteroid dose for the treatment of refractory diabetic macular oedema (DMO). The aim of this study was to assess the impact of an FAc intravitreal implant on intraocular pressure (IOP). METHODS: We retrospectively collected anonymised data on the patients' characteristics, DMO treatment, and IOP and IOP-lowering treatments before and after the FAc intravitreal implant between September 2013 and March 2020 in several European centres. RESULTS: A total of 221 eyes from 179 patients were included. The mean follow-up duration was 13.4 (± 12.5, range 2.4-33.5) months. Overall, 194 eyes (88.2%) had received an intravitreal dexamethasone injection before the FAc intravitreal implant. For 25 eyes (11.3%) there was a history of glaucoma, and 52 eyes (23.5%) had previous IOP-lowering treatment. Mean IOP before injection was 14.7 (3.4) mmHg and increased to 16.9 (3.7) mmHg 12 months after injection (P < 0.0001). During follow-up, 55 eyes (24.9%) required the addition or initiation of topical IOP-lowering medication, only one patient (0.5%) had laser trabeculoplasty and one patient (0.5%) a minimally invasive glaucoma surgery, and no patient required incisional IOP-lowering surgery. CONCLUSION: The FAc intravitreal implant led to substantial IOP elevation. This elevation was monitored most of the time with addition or initiation of topical IOP-lowering medication